The nasal route offers a number of benefits over some of the traditional routes of administration for biologics. This includes rapid delivery into the bloodstream, the avoidance of first pass metabolism, the ability to self-administer and the added potential of bypassing the blood-brain barrier, achieving direct delivery into the brain/CNS.

In recent years there has been an upsurge in interest in delivering a wide range of different classes of molecules via the nasal route. This interest encompasses not only small molecule API’s but also larger biologics such as peptides, proteins, vaccines and oligonucleotides.

Interest in nasal delivery of biologics has been fuelled by the emergence of new dry powder devices and the use of spray drying as the method of choice to engineer stable dry powder products. 

These spray dried formulations can create stable, dry powder dosage forms incorporating even the most sensitive biological molecules along with selected excipients needed to enhance delivery to the target regions in the body. 

Spray dried nasal formulations have the ability to offer excellent stability, targeted nasal deposition, enhanced permeation with a tried and tested route to commercial scale manufacture.

Download the white paper to read more.